...
首页> 外文期刊>Life sciences >24, 25-dihydroxycholecalciferol but not 25-hydroxycholecalciferol suppresses apolipoprotein A-I gene expression.
【24h】

24, 25-dihydroxycholecalciferol but not 25-hydroxycholecalciferol suppresses apolipoprotein A-I gene expression.

机译:24、25-二羟基胆钙化固醇而不是25-羟基胆钙化固醇抑制载脂蛋白A-1基因表达。

获取原文
获取原文并翻译 | 示例

摘要

AIMS: Ligands for the vitamin D receptor (VDR) regulate apolipoprotein A-I (apo A-I) gene expression in a tissue-specific manner. The vitamin D metabolite 24, 25-dihydroxycholecalciferol (24, 25-(OH)(2)D(3)) has been shown to possess unique biological effects. To determine if 24, 25-(OH)(2)D(3) modulates apo A-I gene expression, HepG2 hepatocytes and Caco-2 intestinal cells were treated with 24, 25-(OH)(2)D(3) or its precursor 25-OHD(3). MAIN METHODS: Apo A-I protein levels and mRNA levels were measured by Western and Northern blotting, respectively. Changes in apo A-I promoter activity were measured using the chlorampenicol acetytransferase assay. KEY FINDINGS: Treatment with 24, 25-(OH)(2)D(3), but not 25-OHD(3), inhibited apo A-I secretion in HepG2 and Caco-2 cells and apo A-I mRNA levels and apo A-I promoter activity in HepG2 cells. To determine if 24, 25-(OH)(2)D(3) represses apo A-I gene expression through site A, the nuclear receptor binding element that is essential for VDRs effects on apo A-I gene expression, HepG2 cells were transfected with plasmids containing or lacking site A. While the site A-containing plasmid was suppressed by 24, 25-(OH)(2)D(3), the plasmid lacking site A was not. Likewise, treatment with 24, 25-(OH)(2)D(3) suppressed reporter gene expression in cells transfected with a plasmid containing site A in front of a heterologous promoter. Finally, antisense-mediated VDR depletion failed to reverse the silencing effects of 24, 25-(OH)(2)D(3) on apo A-I expression. SIGNIFICANCE: These results suggest that the vitamin D metabolite 24, 25-(OH)(2)D(3) is an endogenous regulator of apo A-I synthesis through a VDR-independent signaling mechanism.
机译:目的:维生素D受体(VDR)的配体以组织特异性方式调节载脂蛋白A-I(apo A-I)基因表达。维生素D代谢物24、25-二羟基胆钙化固醇(24,25-(OH)(2)D(3))已显示具有独特的生物学作用。为了确定24、25-(OH)(2)D(3)是否调节apo AI基因表达,分别用24、25-(OH)(2)D(3)或其混合物处理了HepG2肝细胞和Caco-2肠细胞。前体25-OHD(3)。主要方法:分别通过Western和Northern印迹法测定Apo A-1蛋白水平和mRNA水平。使用氯霉素乙酰转移酶测定法测量apo A-1启动子活性的变化。主要发现:用24,25-(OH)(2)D(3)而不是25-OHD(3)处理可抑制HepG2和Caco-2细胞中apo AI分泌以及apo AI mRNA水平和apo AI启动子活性在HepG2细胞中为了确定24、25-(OH)(2)D(3)是否通过位点A抑制apo AI基因表达,该位点是VDR对apo AI基因表达所必需的核受体结合元件,将HepG2细胞转染有含有位点A的质粒被24、25-(OH)(2)D(3)抑制,而没有位点A的质粒则没有。同样,用24、25-(OH)(2)D(3)处理可抑制在异源启动子前面含有A位点的质粒转染的细胞中的报告基因表达。最后,反义介导的VDR耗竭未能逆转24、25-(OH)(2)D(3)对apo A-I表达的沉默作用。意义:这些结果表明维生素D代谢物24,25-(OH)(2)D(3)是通过VDR独立信号传导机制对apo A-I合成的内源性调节剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号